173 related articles for article (PubMed ID: 23715628)
1. Expression and clinical significance of FOXE1 in papillary thyroid carcinoma.
Fan Y; Ding Z; Yang Z; Deng X; Kang J; Wu B; Zheng Q
Mol Med Rep; 2013 Jul; 8(1):123-7. PubMed ID: 23715628
[TBL] [Abstract][Full Text] [Related]
2. Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.
Bychkov A; Saenko V; Nakashima M; Mitsutake N; Rogounovitch T; Nikitski A; Orim F; Yamashita S
Thyroid; 2013 Jul; 23(7):817-28. PubMed ID: 23327367
[TBL] [Abstract][Full Text] [Related]
3. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
4. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
5. Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.
Bullock M; Duncan EL; O'Neill C; Tacon L; Sywak M; Sidhu S; Delbridge L; Learoyd D; Robinson BG; Ludgate M; Clifton-Bligh RJ
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1814-9. PubMed ID: 22736773
[TBL] [Abstract][Full Text] [Related]
6. FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA.
Ding Z; Ke R; Zhang Y; Fan Y; Fan J
Mol Cell Endocrinol; 2019 Aug; 493():110420. PubMed ID: 31129275
[TBL] [Abstract][Full Text] [Related]
7. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
8. Expression of HIF-1α and HIF-2α correlates to biological and clinical significance in papillary thyroid carcinoma.
Liu YM; Ying SP; Huang YR; Pan Y; Chen WJ; Ni LQ; Xu JY; Shen QY; Liang Y
World J Surg Oncol; 2016 Feb; 14(1):30. PubMed ID: 26846782
[TBL] [Abstract][Full Text] [Related]
9. FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.
Ma J; Huang X; Li Z; Shen Y; Lai J; Su Q; Zhao J; Xu J
J Cell Physiol; 2019 Aug; 234(10):17739-17748. PubMed ID: 30793770
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
12. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
13. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
15. Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma.
Kallel R; Belguith-Maalej S; Akdi A; Mnif M; Charfeddine I; Galofré P; Ghorbel A; Abid M; Marcos R; Ayadi H; Velázquez A; Hadj Kacem H
Cancer Biomark; 2010-2011; 8(1):43-51. PubMed ID: 21896990
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression.
Batista FA; Ward LS; Marcello MA; Martins MB; Peres KC; Torricelli C; Bufalo NE; Soares FA; da Silva MJ; Assumpção LV
J Endocrinol Invest; 2016 Apr; 39(4):423-9. PubMed ID: 26370671
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma.
Lam AK; Lo CY; Leung P; Lang BH; Chan WF; Luk JM
Ann Surg Oncol; 2007 May; 14(5):1772-9. PubMed ID: 17195959
[TBL] [Abstract][Full Text] [Related]
18. Expression of MAGE A1-6 and the clinical characteristics of papillary thyroid carcinoma.
Lee HS; Kim SW; Hong JC; Jung SB; Jeon CH; Park JW; Park SY; Lee KD
Anticancer Res; 2013 Apr; 33(4):1731-5. PubMed ID: 23564824
[TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
20. Papillary Thyroid Carcinoma: Association Between Germline DNA Variant Markers and Clinical Parameters.
Jendrzejewski J; Liyanarachchi S; Nagy R; Senter L; Wakely PE; Thomas A; Nabhan F; He H; Li W; Sworczak K; Ringel MD; Kirschner LS; de la Chapelle A
Thyroid; 2016 Sep; 26(9):1276-84. PubMed ID: 27342578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
